Page 1

For personal use only TELIX PHARMACEUTICALS Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401 , 55 Flemington Road North Melbourne Victoria , 3051 Australia Activities Report and Appendix 4C for June 2021 Quarter Melbourne ( Australia ) - 22 July 2021. Telix Pharmaceuticals Limited ( ASX : TLX , ‘ Telix ' , the ' Company ' ) today provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2021. All figures are in AUD unless otherwise stated . Financial Summary • Telix held cash reserves of $ 49.62 million on 30 June 2021 ( $ 61.42 million held on 31 March 2021 ) . • Operating expenditure during the quarter was $ 12.80 million , in line with forecasts , with $ 8.25 million invested in R & D and clinical development activities . • Cash runway for approximately 4 quarters of operations based on net cash used in operations in June 2021 quarter and exclusive of any anticipated revenue from sales of an approved product . • Telix has sufficient cash reserves at hand to fund the commercial launch of Illuccix® ( TLX591- CDX ) .1 • Australian Federal Government R & D tax return has been filed . Refund of ~ $ 12 million expected during the September 2021 quarter . Continued progress towards commercialisation made during Q2 2021 Telix has continued its progress in transitioning to a commercial - stage , revenue generating company . At a macro level , this included the establishment of an Asia - Pacific ( APAC ) operating region in May , a restructuring of the business designed to support this transition , and the Company's rapid commercial development . With interest and activity building in the field of prostate cancer molecularly targeted radiation ( MTR ) for both diagnostic and therapeutic use , Telix has been working closely with suppliers and distribution partners to ensure that the roll - out of IlluccixⓇ , its first commercial product , is delivered seamlessly and without delay , subject to requisite regulatory approvals worldwide . IlluccixⓇ - Commercial Launch Activities IlluccixⓇ , an investigational diagnostic imaging agent for PSMA² - PET³ imaging of prostate cancer , will be Telix's first commercial product . PSMA - PET imaging represents the latest standard of care for prostate cancer imaging , having recently been included in clinical practice guidelines in the United States and Europe.4 As at the end of the quarter , marketing authorisation applications for IlluccixⓇ were under review and progressing in 17 countries ( United States , Canada , 13 European member states + UK , and Australia ) . Key regulatory and clinical activity during the quarter , included a late - cycle review meeting with the U.S. Food and Drug Administration ( FDA ) , which took place in June , regarding the ongoing review 1 Subject to approvals in the relevant jurisdictions . None of Telix's products have attained a marketing authorisation in any country . 2 Prostate specific membrane antigen . 3 Positron Emission Tomography . 4 Trabulsi EJ et al . J Clin Oncol . Jan 2020. European Association of Urology 2020 . Page 1